论文部分内容阅读
变应性鼻炎(AR)是临床的一大顽症,发病率高达11%,2001年问世的ARIA指南针对不同类型AR提出了阶梯治疗方案[1],经过两次修订,2010年最新版的ARIA指南应用了GRADE评价体系,将鼻用糖皮质激素和口服H1受体拮抗剂列为治疗AR的强推荐用药[2]。根据高质量的循证医学证据来治疗AR理应取得不错的疗效,但临床的实际情况不容乐观:近半数患者认为医师与之交流时间过短;患者对鼻用糖皮质激素的使用心存顾虑;患者中不严格遵医嘱的比例甚高[3~5]。由此可见,AR当前的治疗缺乏规
Allergic rhinitis (AR) is a clinically significant chronic disease with a high prevalence of up to 11%. The ARIA guidelines, introduced in 2001, provide a step-by-step treatment plan for different types of AR [1]. After two revisions, the latest version of ARIA 2010 The guidelines apply the GRADE evaluation system, which lists nasal glucocorticoid and oral H1 receptor antagonists as strong recommended regimens for the treatment of AR [2]. According to evidence-based medical evidence of high quality of treatment AR should achieve good results, but the clinical situation is not optimistic: nearly half of the patients think the doctor exchanges time is too short; patients with nasal glucocorticoid use and care; Patients do not strictly follow the doctor’s advice is very high [3 ~ 5]. This shows that AR current lack of regulation of the rules